Ascendis Pharma A/S
ASND
228.41
+2.36
+1.04%
Ascendis Pharma A/S
US · ASND
#1127 by market cap
Listed 2015
228.41
+2.36
+1.04%
Live - 5344 symbols - heartbeat 260s ago
· 2026-10-08 07:01
Pre-market
229.00
+0.26%
After-hours
228.41
0.00%
Overnight
229.84
+0.63%
- Market cap
- 15.03B
- P/E (TTM)i
- 18.23
- P/Bi
- 9.35
- EPSi
- -4.21
- Div yieldi
- 0.00%
- 52W posi
- 44%
Reader sentiment
Are you bullish or bearish on ASND?
Anonymous reader poll. Unscientific, not investment advice.
Analyst consensus 18 analysts
Buy
Avg price target
317.47 +39.0%
Price target rangecurrent 228.41
Low273.00
Avg317.47
High360.00
Buy 100%
Hold 0%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-09-30 | Barclays | -- | BUY | 329.00 |
| 2026-09-28 | Morgan Stanley | -- | BUY | 273.00 |
| 2026-09-25 | Cantor Fitzgerald | -- | BUY | 300.00 |
| 2026-09-21 | Morgan Stanley | -- | BUY | 273.00 |
| 2026-09-16 | Wedbush | -- | BUY | 327.00 |
| 2026-09-16 | H.C. Wainwright | -- | BUY | 344.00 |
| 2026-09-15 | Raymond James | -- | BUY | 287.00 |
| 2026-09-15 | BofA Securities | -- | BUY | 304.00 |
| 2026-09-15 | J.P. Morgan | -- | BUY | -- |
| 2026-09-14 | Morgan Stanley | -- | BUY | 273.00 |
| 2026-09-14 | BMO Capital | -- | BUY | 319.00 |
| 2026-09-10 | H.C. Wainwright | -- | BUY | 344.00 |
| 2026-09-08 | Morgan Stanley | -- | BUY | 273.00 |
| 2026-09-02 | Oppenheimer | -- | BUY | 312.00 |
| 2026-09-01 | Morgan Stanley | -- | BUY | 273.00 |
| 2026-09-01 | Stifel | -- | BUY | 326.00 |
| 2026-09-01 | H.C. Wainwright | -- | BUY | 344.00 |
| 2026-08-31 | BofA Securities | -- | BUY | 304.00 |
| 2026-08-31 | Wedbush | -- | BUY | 327.00 |
| 2026-08-31 | Morgan Stanley | -- | BUY | 273.00 |
| 2026-08-31 | Jefferies | -- | BUY | 330.00 |
| 2026-08-31 | H.C. Wainwright | -- | BUY | 344.00 |
| 2026-08-31 | J.P. Morgan | -- | BUY | -- |
| 2026-08-27 | H.C. Wainwright | -- | BUY | 345.00 |
| 2026-08-24 | Morgan Stanley | -- | BUY | 275.00 |
Quant vs Street three independent views, side by side
StockVane factor grade
D-
Momentum strategy signal
Sell
Analyst consensus
Buy
Mostly aligned, one view stands apart.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
Price target trend monthly average, last 3 years
Earnings history price reaction on the day
| Period | Report date | Session | Options expected | Actual move |
|---|---|---|---|---|
| 2026/Q2 | 2026-08-13 | -- | ±6.17% | -3.61% (in line) |
| 2026/Q1 | 2026-05-07 | -- | ±7.59% | +4.34% (in line) |
| 2025/Q4 | 2026-02-11 | After close | ±6.18% | -1.53% (in line) |
| 2025/Q3 | 2025-11-12 | After close | ±8.17% | +3.63% (in line) |
| 2025/Q2 | 2025-08-07 | After close | ±12.00% | +0.60% (in line) |
| 2025/Q1 | 2025-05-01 | After close | ±10.36% | +2.74% (in line) |
| 2024/Q4 | 2025-02-12 | After close | ±7.92% | +12.96% (beat) |
| 2024/Q3 | 2024-11-14 | After close | ±21.02% | +1.79% (in line) |
| 2024/Q2 | 2024-09-03 | After close | ±9.85% | -11.27% (beat) |
| 2024/Q1 | 2024-05-02 | After close | ±21.81% | -2.76% (in line) |
| 2023/Q4 | 2024-02-07 | After close | ±10.41% | -0.03% (in line) |
| 2023/Q3 | 2023-11-07 | After close | ±9.47% | -1.47% (in line) |
"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.
Quote time 2026-10-08 07:01:58 · For reference only, not investment advice and not tailored to your situation.